Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
- PDF / 292,615 Bytes
- 7 Pages / 595.28 x 793.7 pts Page_size
- 60 Downloads / 142 Views
MEETING REPORT
Open Access
Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011 Ivan Martinez Forero1, Hideho Okada2, Suzanne L Topalian3, Thomas F Gajewski5, Alan J Korman4 and Ignacio Melero6*
Abstract Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinations in the clinic may still face formidable challenges in regulatory, drug-availability and intellectual property aspects. The 2011 SITC annual meeting hosted a workshop on combination immunotherapy to discuss: 1) the most promising combinations found in the laboratory; 2) early success of combination immunotherapy in clinical trials; 3) industry perspectives on combination approaches, and 4) relevant regulatory issues. The integrated theme was how to accelerate the implementation of efficacious combined immunotherapies for cancer patients. Rodent animal models are providing many examples of synergistic combinations that typically include more than two agents. However, mouse and human immunology differ in a significant number of mechanisms and hence we might be missing opportunities peculiar to humans. Nonetheless, incisive animal experimentation with deep mechanistic insight remains the best compass that we can use to guide our paths in combinatorial immunotherapy. Combination immunotherapy clinical trials are already in progress and preliminary results are extremely promising. As a key to translate promising combinations into clinic, real and “perceived” business and regulatory hurdles were debated. A formidable step forward would be to be able to test combinations of investigational agents prior to individual approval. Taking together the FDA and the industrial perspective on combinatorial immunotherapy, the audience was left with the clear message that this is by no means an impossible task. The general perception is that the road ahead of us is full of combination clinical trials which hopefully will bring clinical benefit to our cancer patients at a fast pace. Keywords: Immunotherapy, Combination immunotherapy, Cancer vaccines, Chemotherapy, Anti-CTLA4, Anti-PD/PD-L1
The need for immunotherapy combinations The long quest to attain clinical benefit in cancer patients by activating the immune system against such a deadly disease is finally paying off [1,2]. Exciting results have been recently reported with immunostimulatory monoclonal antibodies (mAbs) [3–6], with cancer vaccines [7] and with adoptive T cell therapies [8,9]. Success and optimistic perspectives have brought steadily increasing industrial interest in this area of research. At this point in time the private and public sectors are * Correspondence: [email protected] 6 Clinica Universidad de Navarra, Pamplona, Spain Full list of author information is available at the end of the article
mo
Data Loading...
